# Commission Regulation (EC) No 2049/2005 of 15 December 2005 laying down, pursuant to Regulation (EC) No 726/2004 of the European Parliament and of the Council, rules regarding the payment of fees to, and the receipt of administrative assistance from, the European Medicines Agency by micro, small and medium-sized enterprises (Text with EEA relevance), Article 8: Fee reduction for the establishment of maximum residue limits for veterinary medicinal products

Extent: E+W+S+N.I.

1. A 90 % reduction shall apply to the full and additional maximum residue limits (MRL) fees, as referred to in Article 7 of Regulation (EC) No 297/95.
2. The reduction referred to in paragraph 1 shall not be taken into account when calculating the deduction of the MRL fees from the fee payable for an application for a marketing authorisation or an application to extend a marketing authorisation, for a medicinal product containing the substance for which the MRL concerned has been set, where such applications are submitted by the same applicant.
However, this deduction shall not exceed one half of the fee to which it applies.

---
Source: https://www.legislation.gov.uk/eur/2005/2049/article/8 (the official version)
Page: https://openlegislation.uk/eu-regulation-2005-2049/article-8
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.